Adrian Rawcliffe, Chief Executive Officer at Adaptimmune Therapeutics PLC (ADAP), sold 59,569 shares at $0.59 ($35K) on 2025-01-13, disclosed to the SEC on 2025-01-15.
Seasonal sale ($35k) by Chief Executive Officer — this insider has traded ADAP in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.59 | 12,539 | $7K | 21.4% |
| 2 | $0.59 | 17,934 | $11K | 30.6% |
| 3 | $0.57 | 29,096 | $17K | 48.0% |
| Total | $0.58 avg | 59,569 | $35K | 100% |
| Filing → |
| WVE | SELL | 2025-11-14 | $219K | — | Filing → |
| ADAP | SELL | 2025-01-17 | $18K | — | Filing → |
| ADAP | SELL | 2024-01-17 | $28K | — | Filing → |